http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110179868-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1012835eb9a0f189bbf6762f8b3f3e52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-714 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-258 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-714 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2019-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49906babf026c3ff90386410d891194b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec3f2dcff09bbef8fb6307c420030ed3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c2e8f2b483dbafda936ecea189e35c5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eebb516ae710f46160f5571a2f769b8c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_391eed1fbde8c8c4387bcec3185f1744 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_733e4ed70d129ec77836cf7afda1e902 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5396e29b8cf8bed15bdbf273d0176740 |
| publicationDate | 2019-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110179868-A |
| titleOfInvention | Shenfu drug combination for the treatment of heart failure |
| abstract | The invention relates to the technical field of medical treatment and traditional Chinese medicine, and in particular, provides a Shenfu medicine combination for treating heart failure. The Shenfu drug combination for treating heart failure, wherein the Shenfu drug combination is an oral dosage form, mainly made of ginseng and aconite, and the mass ratio of ginseng and aconite is (1.5-2.5):1. During the research and development work, the inventor found that due to the influence of factors such as first-pass effect and absorption distribution, the ratio of pharmaceutical raw materials for injection administration and oral administration is not necessarily the same. In the treatment of heart failure, for the convenience of patients, it is more convenient and convenient to take the combination of ginseng and aconite in the form of oral medicine. At the same time, when the mass ratio of ginseng and aconite is (1.5-2.5): 1, the effect is the best. At the same time, the formula causes the weakest cardiotoxicity in the body, and has the least impact on heart rate, cardiac contraction and other functions. Compared with other formulations, it has significant curative effect and lower toxicity. |
| priorityDate | 2019-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.